KRYS today
$308.81+$2.31 (+0.75%)close Nov 11, 2026Trend
DailyDowntrend (starting)
4 hourBullish
1 hourLeaning Bullish
15 minLeaning Bearish
5 minConsolidating
Daily trend turns up above $373.31
Key levels
Resistance$332.63
Resistance$309.63
Support$297.02
Support$281.40
Latest news & SEC filings
AnalystAnalysts revise Krystal Biotech price targets after Q3 results
AnalystCitigroup keeps Buy rating on Krystal Biotech, cuts price target to $412
All KRYS news →About Krystal Biotech
Krystal Biotech is a commercial-stage biotechnology company that creates genetic medicines using an engineered herpes simplex virus-1 vector platform. Its approved product, VYJUVEK, is a topical gene therapy for dystrophic epidermolysis bullosa, sold in the United States, Europe, and Japan. The company also has clinical-stage candidates for rare diseases and is exploring its platform for more widespread severe illnesses and aesthetic uses through its Jeune Aesthetics subsidiary. It runs its own manufacturing facilities in Pennsylvania.
Based on the company's 10-K filed Feb 17, 2026.
Nasdaq · Healthcare
Krystal Biotech, Inc. (KRYS)
What Is the Price Target for KRYS?
SEPT Low Target
$300.00
SEPT Mid Target
$375.00
SEPT High Target
$412.00
Analyst Consensus
$375.00
Is KRYS a Buy or Sell Right Now?
Thesis
- •Revenue growing 33.9% YoY with STRONG trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for KRYS.
Start Free Trial →Is KRYS Overvalued or Undervalued?
Valuation Verdict
FAIR
Methods Used
P/E Forward, P/B, PEG, Analyst Consensus
Fair Value
$340.75
55
Moat Score
NARROW
6/9
Piotroski Score
53.8
Altman Z-Score
What Is Smart Money Doing with KRYS?
Insider Signal
SELLING
0 buys / 20 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Krishnan Suma | director officer 10% owner | Sale | 520 | $184K | Sep 4, 2026 |
| Krishnan Suma | director officer 10% owner | Sale | 2,006 | $713K | Sep 4, 2026 |
| Krishnan Suma | director officer 10% owner | Sale | 3,267 | $1.2M | Sep 4, 2026 |
| Krishnan Suma | director officer 10% owner | Sale | 3,962 | $1.4M | Sep 4, 2026 |
| Krishnan Suma | director officer 10% owner | Sale | 3,180 | $1.1M | Sep 4, 2026 |
| Krishnan Suma | director officer 10% owner | Sale | 3,392 | $1.2M | Sep 4, 2026 |
| Krishnan Suma | director officer 10% owner | Sale | 2,320 | $836K | Sep 4, 2026 |
| Krishnan Suma | director officer 10% owner | Sale | 1,242 | $449K | Sep 4, 2026 |
| Krishnan Suma | director officer 10% owner | Sale | 1,992 | $722K | Sep 4, 2026 |
| Krishnan Suma | director officer 10% owner | Sale | 565 | $205K | Sep 4, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →KRYS Growth Story
Revenue YoY
33.9%
3yr Revenue CAGR
N/A%
EPS Growth YoY
128%
FCF Growth YoY
58.5%
Revenue Trend
STRONG
Dark Pool Trades for KRYS
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for KRYS, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:45:27 | $310.51 | 1,292 | $$401K | SELL |
| 21:00:09 | $306.50 | 1,313 | $$402K | BUY |
| 21:00:09 | $306.50 | 1,261 | $$386K | BUY |
| 21:09:47 | $301.54 | 3,591 | $$1.1M | BUY |
| 21:04:55 | $303.06 | 2,664 | $$807K | BUY |
5 dark pool trades shown · $$3.1M preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for KRYS
PREVIEWSEPT Investing provides real-time options flow tracking for KRYS, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| PUT | $310 | Dec 18 | 37 | $$1610 | 1 | SWEEP |
1 options trades shown · 0% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Krystal Biotech, Inc. (KRYS) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →KRYS — frequently asked questions
What is KRYS stock price today?
Krystal Biotech, Inc. (KRYS) is at $308.81, up 0.75% (+$2.31) at the Nov 11, 2026 close.
Why is KRYS stock moving today?
Latest KRYS news — Nov 3, 2026: Analysts revise Krystal Biotech price targets after Q3 results · Nov 3, 2026: Citigroup keeps Buy rating on Krystal Biotech, cuts price target to $412
What is the KRYS price target?
The average analyst price target for KRYS is $375.00, ranging from $300 to $412, based on 7 analysts. Latest: Citigroup maintains on Nov 3, 2026.
What do analysts rate KRYS?
Analyst ratings for KRYS: 0 Buy, 14 Hold, 0 Sell — consensus Hold.
Did KRYS beat earnings?
KRYS last reported on Nov 2, 2026: EPS $2.05 vs $1.79 expected — a beat of 14.5%.
What is KRYS's P/E ratio?
KRYS trades at a P/E of 41.0 vs a Healthcare average of 17.8.
Does KRYS pay a dividend?
KRYS does not currently pay a dividend.
What are KRYS support and resistance levels?
Support: $297.02, $281.40, $265.65. Resistance: $309.63, $332.63, $353.84.
What are insiders doing with KRYS?
Insider activity: SELLING, 0 buys and 20 sells in the last 90 days.
What is the latest news on KRYS?
Nov 3, 2026: Analysts revise Krystal Biotech price targets after Q3 results · Nov 3, 2026: Citigroup keeps Buy rating on Krystal Biotech, cuts price target to $412